(8-091) Multiple Switching Between the Biosimilar Adalimumab PF-06410293 and High Concentration Reference Adalimumab in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis

Tuesday, December 6, 2022

2:00 PM – 3:30 PM

Location: Bayside A, Level 1

Category: Evaluative Study
Topic: Clinical Topics/Therapeutics

Co-Author(s): Daniel F. Alvarez, Donna S. Cox, Karen Wang, Wuyan Zhang

Primary Author(s)

Mark Latymer, BSc
Senior Global Medical Director, Biosimilars Portfolio
Pfizer Biopharmaceuticals Group, England, United Kingdom